The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial
| Autor: | Linda Mellbin, Kurt Boman, Shun Fu Lee, Hertzel C. Gerstein, Jenny Hernestål-Boman, Aslak Rautio, Mona Olofsson |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Blood Glucose
Male Oncology medicine.medical_specialty Time Factors Endocrinology Diabetes and Metabolism medicine.medical_treatment Insulin Glargine 030204 cardiovascular system & hematology Tissue plasminogen activator 03 medical and health sciences 0302 clinical medicine Von Willebrand factor Risk Factors Internal medicine Diabetes mellitus Glucose Intolerance Plasminogen Activator Inhibitor 1 von Willebrand Factor Fibrinolysis Internal Medicine medicine Humans Hypoglycemic Agents 030212 general & internal medicine Intervention trial Aged Sweden biology Insulin glargine business.industry Basal insulin Middle Aged medicine.disease Treatment Outcome Endocrinology Diabetes Mellitus Type 2 Cardiovascular Diseases Tissue Plasminogen Activator biology.protein Female Cardiology and Cardiovascular Medicine business Plasminogen activator Biomarkers medicine.drug |
| Zdroj: | Diabetes and Vascular Disease Research. 14:345-352 |
| ISSN: | 1752-8984 1479-1641 |
| Popis: | Introduction: Fibrinolytic factors, plasminogen activator inhibitor-1, tissue plasminogen activator, tissue plasminogen activator/plasminogen activator-complex and the haemostatic factor von Willebrand factor are known markers of cardiovascular disease. Their plasma levels are adversely affected in patients with dysglycaemia, and glucose normalization with insulin glargine might improve the levels of these factors. Methods: Prespecified Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial (ClinicalTrials.gov number, NCT00069784). Tissue plasminogen activator activity, tissue plasminogen activator antigen, plasminogen activator inhibitor-1 antigen, tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor were analysed at study start, after 2 years and at the end of the study (median follow-up of 6.2 years). Results: Of 129 patients (mean age of 64 ± 7 years, females: 19%), 68 (53%) and 61 (47%) were randomized to the insulin glargine and standard care group, respectively. Allocation to insulin glargine did not significantly affect the studied fibrinolytic markers or von Willebrand factor compared to standard care. Likewise, there were no significant differences in plasminogen activator inhibitor-1, tissue plasminogen activator antigen and von Willebrand factor. During the whole study period, the within-group analysis revealed a curvilinear pattern and significant changes for tissue plasminogen activator/plasminogen activator inhibitor-1 complex, tissue plasminogen activator antigen and von Willebrand factor in the insulin glargine but not in the standard care group. Conclusion: In people with dysglycaemia and other cardiovascular risk factors, basal insulin does not improve the levels of markers of fibrinolysis or von Willebrand factor compared to standard glucose-lowering treatments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|